TOKYO -- The head of Japanese pharmaceutical company Eisai plans to submit an application for approval in fiscal 2022 for a new Alzheimer's treatment being developed with U.S. partner Biogen.
"One clinical trial was delayed due to the impact from the novel coronavirus, but it has largely gone smoothly," Eisai CEO Haruo Naito told Nikkei in an interview. "We'll compile the final results during the July-September quarter in 2022."
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
